Stockscreener 앱 받기
186.60
1.43%
-2.09
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Deutsche Bank Adjusts Jazz Pharmaceuticals Price Target to $226 From $225, Maintains Buy Rating - marketscreener.com
GW&K Investment Management LLC Sells 17,849 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Mixed Recent Returns And A 5.7% Undervaluation Estimate - simplywall.st
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
JAZZ SEC FilingsJazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms - Stock Titan
https://www.msn.com/en-us/money/companies/jazz-pharmaceuticals-plc-jazz-reports-1-2-billion-q4-revenue-beats-1-17b-estimate/ar-AA1Xsvc3?ocid=finance-verthp-feeds - MSN
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate - Yahoo! Finance Canada
Jazz Pharmaceuticals (NASDAQ: JAZZ) lists option-derived shares for sale via Merrill Lynch - Stock Titan
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 36% One Year Share Price Jump - simplywall.st
JAZZ: Record growth, pipeline advances, and rare disease focus drive strong 2026 outlook - TradingView
JAZZ: Record growth, pipeline advances, and new filings drive strong outlook for 2026 - TradingView
JAZZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares - MarketBeat
Jazz Pharmaceuticals Director Sells 3,415 Shares - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 55,600 Shares - MarketBeat
Jazz Pharmaceuticals (JAZZ) director sells 3,415 shares after option exercise - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,117 Shares - MarketBeat
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Sells 5,343 Shares of Stock - MarketBeat
Patricia Carr Sells 1,253 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Jazz Pharmaceuticals (JAZZ) CFO granted 11,857 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP awarded 9,782 restricted stock units in Form 4 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports share award and open-market sales - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO receives 44,465 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) director receives 1,527-share restricted stock unit grant - Stock Titan
Jazz Pharmaceuticals Insider Sold Shares Worth $1,039,134, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (NASDAQ: JAZZ) EVP Patil sells 55,600 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports RSU grant and tax-driven share sale - Stock Titan
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth - Sleep Review
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unveiling A 17% Upside Potential For Investors - DirectorsTalk Interviews
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Revenue And New Oncology Data Release - simplywall.st
JAZZ Should I Buy - Intellectia AI
Patricia Carr reports JAZZ (NASDAQ: JAZZ) sales of 1,253 and 4,660 shares - Stock Titan
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
JAZZ Receives New Overweight Rating as Barclays Initiates Coverage | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Stock Surges 13% on Oncology Breakthrough: Here’s Where the Stock Could Go in 2026 - TIKR.com
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock? - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Quarterly Profit Of US$203 Million Tests Trailing Loss Narrative - simplywall.st
Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144: 10,116 restricted shares; insider sold 2,238 - Stock Titan
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise’s Outlook (NASDAQ:JAZZ) - Seeking Alpha
Fox Run Management L.L.C. Invests $1.37 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Citigroup Inc. - MarketBeat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Quarter And 2026 Guidance - Yahoo Finance
Jazz Pharmaceuticals stock hits 52-week high at $183.10 By Investing.com - Investing.com Australia
No-Moat Jazz's Growth Driven by Newly Launched Assets and Pending Expansion of Ziihera - Morningstar
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why - Finviz
Jazz Pharmaceuticals’ Stock Set to Climb Post Stellar Earnings - StocksToTrade
Jazz Pharmaceuticals Sees Record Revenue, Analyst Ups Price Target - timothysykes.com
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After 2025 Results And 2026 Revenue Guidance - simplywall.st
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations - Finviz
Jazz Pharmaceuticals jumps after record 2025 results, upbeat 2026 guidance and fresh analyst target hikes - Quiver Quantitative
JAZZ Stock Sees Revised Price Target by RBC Capital | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $195.00 at Royal Bank Of Canada - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat
Morgan Stanley Forecasts Strong Price Appreciation for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Wells Fargo Raises Price Target on Jazz Pharmaceuticals (JAZZ) t - GuruFocus
Jazz Pharmaceuticals stock hits 52-week high at $183.10 - Investing.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
Jazz Pharmaceuticals Excels with Record 2025 Revenue, Positive Outlook for 2026 - StocksToTrade
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $275.00 at Bank of America - MarketBeat
0.50%
자본화:
|
볼륨(24시간):